50562-02-2

Upstream product

• 405-50-5 p-Fluorophenylacetic acid 
• 34837-84-8 4-fluorobenzeneacetic acid methyl ester 
• 7589-27-7 2-(4-Fluorophenyl)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 676622-00-7 {1-[2-(4-Fluorophenyl)ethyl]-piperidin-3-ylmethyl}carbamic Acid Benzyl Ester 
• 164179-52-6 1-iodo-2-(4-fluorophenyl)ethane 
• 1208109-85-6 1'-[2-(4-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208109-99-2 (2S)-1'-[2-(4-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 311348-79-5 (R)-(-)-α-[2-methoxy-3-[(1,1-dimethylethyl)diphenylsilyl]oxyphenyl]-41-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol 
• 1624333-25-0 (4-fluorophenethyl)(trifluoromethyl)thioether 
• 1570277-04-1 C₂₂H₂₄FN₃ 
• 1443128-48-0 C₂₉H₃₃FO₅ 
• 1443128-26-4 C₂₉H₃₁FO₆ 
• 267643-97-0 (S)-N-methyl-N-(1-(2-(4-fluorophenyl)ethyl)pyrrolidin-3-yl)-1-adamantanecarboxamide hydrochloride 
• 1096811-24-3 3-methylamino-1-(2-(4-fluorophenyl)ethyl)pyrrolidine 

Relevant academic research and scientific papers

Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-ones as potassium-competitive acid blockers

With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-one derivatives, which could occupy two important lipophilic pockets (described as LP-1 and LP-2) of H+,K+-ATPase and can strongly bind to the K+-binding site, were designed based on a docking model. Among the compounds synthesized, compound 4d showed a strong H+,K+-ATPase-inhibitory activity and a high stomach concentration in rats, resulting in potent inhibitory action on histamine-stimulated gastric acid secretion in rats. Furthermore, 4d exerted significant inhibitory action on histamine-stimulated gastric-acid secretion in rats with a rapid onset and moderate duration of action after the administration. These findings may lead to a new insight into the drug design of potassium-competitive acid blockers.

Substituted fused bicyclic amines as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5′, R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

N-substituted heterocyclic amines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.